Green Bay Packers and Cologuard Launch Colon Cancer Awareness Campaign

Pledging to help increase screening offers fans opportunity to win Packers tickets and prizes

GREEN BAY and MADISON, Wis. – Aug. 16, 2017 – The Green Bay Packers and Exact Sciences, the manufacturer of Cologuard, are teaming up to promote colorectal cancer awareness throughout the 2017 football season. 

Colon cancer took the life of legendary Packers coach Vince Lombardi at age 57 and almost 50 years later remains the number two cancer killer in the United States, according to the U.S. Centers for Disease Control and Prevention.

Read More

Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests

- Revenue guidance raised to $230-240 million for 2017, from $195-205 million
- Guidance for Cologuard tests to be completed during 2017 increased to at least 550,000 tests, from at least 470,000
- 11,000 additional providers ordered Cologuard for the first time during the second quarter, and insurance coverage expanded to 86 percent of target population

MADISON, Wis., July 25, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $57.6 million and completed approximately 135,000 Cologuard tests during the quarter ended June 30, 2017. Second-quarter 2017 revenue and completed Cologuard test volume grew 172 percent and 149 percent from the same period of 2016, respectively.

Read More

Jerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening

Golfer launches multi-year, Cologuard®-branded campaign

MADISON, Wis., June 22, 2017 /PRNewswire/ -- Exact Sciences today announced it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening.  Beginning at this week's American Family Insurance Championship, Kelly will wear a Cologuard-branded hat for the next two years at tournaments around the country to help raise awareness of colon cancer and the importance of regular screening beginning at age 50 for individuals at average risk.

Read More

A Strong Start to 2017

Exact Sciences recently announced our first quarter 2017 financial results, highlighting the accelerating growth trajectory for Cologuard.  Beyond the headline-making news, we continue to see a large market opportunity for Cologuard. While changing the standard of care will take time and investment in our infrastructure, we have never been more confident in the long-term growth of Cologuard and Exact Sciences.  

Read More

Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests

  • Gross margin expands to 65 percent during first quarter
  • Revenue guidance raised to $195-205 million for 2017, from $170-180 million;
  • Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000;
  • 10,000 additional providers ordered Cologuard during the first quarter, and insurance coverage expanded to 78 percent.

MADISON, Wis., April 27, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively.

Read More

Topics: Investor Relations

CMS includes Cologuard in updated Medicare Advantage Star Ratings

 

 

MADISON, Wis., April 4, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive colon cancer screening test. 
 
Read More

Exact Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test

AACR abstract highlights methylation markers capable of detecting all types of lung cancer with more than 90% sensitivity and specificity

MADISON, Wis., March 1, 2017 /PRNewswire/ -- A study from Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic released today by the American Association of Cancer Research (AACR) shows promise for the development of a blood-based lung cancer test. Researchers conducted a multi-round study of nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages.

Read More